Trial Profile
A STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma
- Focus Adverse reactions
- Sponsors Pfizer
- 25 Aug 2019 Status changed from active, no longer recruiting to completed.
- 15 Jul 2019 Planned End Date changed from 22 Jul 2019 to 25 Jul 2019.
- 15 Jul 2019 Planned primary completion date changed from 22 Jul 2019 to 25 Jul 2019.